Du är här

2015-09-03

Eckert & Ziegler BEBIG: Dr. Harald Hasselmann appointed as new managing director of Eckert & Ziegler BEBIG

Seneffe, September 3, 2015. As part of the restructuring measures at medical
technology company Eckert&Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG:BB), the Board of Directors has appointed business
administration expert Dr. Harald Hasselmann (aged 48) as the new commercial
managing director for sales and finances. With effect from October 1, 2015 he
will be a member of the management team and head the company together with
Dr. Edgar Löffler, a medical physicist, who is responsible for the
irradiation equipment manufacturer's technical operations. Abel Luzuriaga,
who has been managing director for sales and marketing at Eckert&Ziegler
BEBIG since 2012, is leaving the company of his own accord.

Harald Hasselmann, born in Hamburg, has gained extensive experience at various
international pharmaceutical companies. He was head of controlling for Europe
at Bayer Pharma, managing director at Schering's Hungarian subsidiary and
director of the Berlin-based biotech company metaGen. He has held various
positions in large and medium-sized healthcare companies and has an excellent
track record in sales, controlling and implementing restructuring measures.

"With Dr. Hasselmann we have won an ideal industry expert who will serve to
substantially enhance our company's skills and capabilities, especially with
regard to implementing our restructuring strategy," explains Dr. Edgar
Löffler, Managing Director of Eckert&Ziegler BEBIG SA. "I am looking forward
to the new challenges at Eckert&Ziegler BEBIG. The emphasis will be on the
segment's profitability and growth at an international level," added Dr.
Harald Hasselmann.

The Board of Directors would like to thank Mr. Luzuriaga for his dedication
and in particular for his involvement in expanding the market for tumor
irradiation equipment.

About Eckert&Ziegler BEBIG

Contributing to saving lives!

Eckert&Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry. Its core business is the production and
distribution of medical products for the treatment of cancer using
brachytherapy. The company headquarters are in Belgium, with production
facilities in Germany and in the USA, as well as subsidiaries throughout
Europe, the USA, India and Brazil. In addition, Eckert&Ziegler BEBIG has a
worldwide network of distributors and agents, to support the international
marketing and distribution of its product line. The company's products and
equipment are intended for use by oncologists, radiotherapists, urologists,
ophthalmologists and medical physicists.
Eckert&Ziegler BEBIG employs approximately 180 people. The company has been
listed on the Euronext stock exchange since April 1997.

Your contact:
Eckert&Ziegler BEBIG SA
Att. Investor Relations&Communications
Tel: +32 64 520 808
Fax: +32 64 520 801
E-mail:ir@bebig.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert&Ziegler BEBIG via Globenewswire

HUG#1949660

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.